Hypercalcemia: Diagnosis and Management (Step-by-Step Clinical Guide for Doctors)

1. Introduction: The Clinical Challenge of Hypercalcemia

Hypercalcemia is a frequent clinical encounter that demands a rigorous diagnostic framework to ensure patient safety and effective intervention. Establishing a correct hypercalcemia diagnosis and management strategy is essential, as the condition often serves as a harbinger of significant underlying systemic disease. 

While primary hyperparathyroidism and malignancy-associated hypercalcemia account for greater than 90% of all cases, a systematic clinical approach is vital for the remaining 10% of etiologies. We must recognize that symptoms often correlate more with the rate of serum calcium rise than with absolute values.

2. Definition and Severity Classification

Hypercalcemia is defined as a total serum calcium level exceeding 2.62 mmol/L (normal range: 2.12–2.62 mmol/L). In practice, we classify severity to guide the urgency of management:

• Mild: <12 mg/dL (3 mmol/L). Often asymptomatic or presenting with vague fatigue.
• Moderate: 12 to 14 mg/dL (3 to 3.5 mmol/L). May be tolerated if chronic, but symptomatic if acute.
• Severe: >14 mg/dL (>3.5 mmol/L). A medical emergency requiring immediate hospitalization and aggressive therapy.

3. Physiology of Calcium Homeostasis

Calcium levels are tightly regulated through the interplay of parathyroid hormone (PTH), vitamin D metabolites (calcidiol and calcitriol), and the bone-kidney-gut axis. Hypercalcemia develops when the entry of calcium into the extracellular fluid—via accelerated bone resorption or excessive intestinal absorption—surpasses the capacity for renal excretion or bone deposition. PTH is the primary driver of bone resorption and renal calcium reabsorption, while calcitriol (1,25-dihydroxyvitamin D) enhances intestinal absorption.

4. Causes of Hypercalcemia

Table 1 shows the causes of hypercalcemia, grouped by their relationship to parathyroid hormone.

PTH-Dependent Causes

• Primary Hyperparathyroidism (PHPT): The most common outpatient cause, typically due to a solitary parathyroid adenoma.
• Tertiary Hyperparathyroidism: Observed in advanced chronic kidney disease (CKD) when parathyroid hyperplasia becomes autonomous.
• Familial Hypocalciuric Hypercalcemia (FHH): A loss-of-function mutation in the calcium-sensing receptor (CaSR) causing inappropriately normal or high PTH despite hypercalcemia.

PTH-Independent Causes

• Malignancy: The leading cause in hospitalized patients.
  • Humoral Hypercalcemia of Malignancy (HHM): Mediated by parathyroid hormone-related protein (PTHrP).
  • Local Osteolysis: Direct bone destruction (e.g., breast cancer, multiple myeloma).
  • Extrarenal Calcitriol: Seen in lymphomas.
• Vitamin D Disorders: Intoxication with vitamin D/calcidiol or granulomatous diseases (sarcoidosis, tuberculosis), where activated macrophages produce calcitriol independent of PTH.
• Medications: Thiazide diuretics (reduced urinary excretion), lithium (increased PTH set point), and vitamin A toxicity (increased bone resorption).
• Other: Thyrotoxicosis, Paget's disease (during immobilization), and milk-alkali syndrome.

5. Clinical Presentation: "Stones, Bones, Groans, and Psychiatric Overtones."

• Renal: Polyuria and polydipsia (nephrogenic diabetes insipidus), nephrolithiasis, and nephrocalcinosis.
• Gastrointestinal (Groans): Constipation, nausea, anorexia, and, less commonly, pancreatitis or peptic ulcers.
• Neuropsychiatric (Psychiatric Overtones): Anxiety, depression, cognitive dysfunction, confusion, and, in severe cases, stupor or coma.
• Cardiovascular: Hypertension, shortened QT interval on ECG, and potentially lethal arrhythmias.
• Musculoskeletal (Bones): Muscle weakness and bone pain.
• Physical Findings: While rare, band keratopathy (subepithelial calcium phosphate deposits in the cornea) may be observed via slit-lamp examination.

6. Diagnostic Approach to Hypercalcemia 

Because approximately 45% of calcium is albumin-bound, the measured total calcium must be corrected for albumin levels. Correction is mandatory to exclude pseudohypercalcemia; clinicians should refer to institutional calculators or measure ionized calcium directly.

The measurement of intact PTH is the pivotal diagnostic step:

• PTH > 20 pg/mL: Suggests PTH-mediated hypercalcemia (primary HPT).
• PTH < 20 pg/mL: Suggests non-PTH-mediated hypercalcemia (malignancy, vitamin D disorders).

If PTH is suppressed, clinicians must evaluate PTHrP, 25(OH)D (calcidiol), and 1,25(OH)₂D (calcitriol).

7. Diagnostic Algorithm

• High Total Calcium -> Correct for Albumin -> Confirmed Hypercalcemia.

• Check Intact PTH:

• Elevated/High-Normal (>20 pg/mL):
• Check 24-hour urine calcium (low excretion/ratio < 0.01 = FHH; high/normal = PHPT).
• Screen for MEN syndromes.

• Low/Suppressed (<20 pg/mL): Check PTHrP and vitamin D metabolites.
• High PTHrP: Humoral Hypercalcemia of Malignancy.
• High 1.25(OH) 2D: Sarcoidosis, Lymphoma, or Granulomatous Disease.
• High 25(OH)D: Vitamin D intoxication.
• All Low: Evaluate for multiple myeloma (SPEP/UPEP), thyrotoxicosis (TSH), vitamin A toxicity, or immobilization.

8. Clinical Laboratory Interpretation Tables

Table 3: Differential Diagnosis by Lab Profile

Table 4: Diagnostic Workup by System

9. Management of Hypercalcemia

General Measures

For calcium <12 mg/dL, avoid thiazides and lithium. Maintain hydration and limit dietary calcium to <1000 mg/day. Note: Thiazides are strictly contraindicated in sarcoidosis as they reduce calcium excretion in a setting of already high intestinal absorption.

Patients should avoid factors that may aggravate the condition, including thiazide diuretics and lithium carbonate therapy, volume depletion, prolonged immobilization, and a high calcium diet (>1000 mg/day). Adequate hydration (at least 6-8 glasses/day) is recommended to decrease the risk of nephrolithiasis.

Management of Severe/Emergency Hypercalcemia

1. Saline Hydration: Isotonic saline (200–300 mL/hour) to maintain urine output of 100–150 mL/hour.
2. Calcitonin: 4 units/kg (IM/SC). If responsive, titrate to 6 to 8 units/kg every 6 to 12 hours. Useful for rapid reduction but limited by tachyphylaxis after 48 hours.
3. Bisphosphonates: Zoledronic acid (4 mg IV over 15 min) is superior to pamidronate (60–90 mg over 2 hours) for malignancy.
4. Dialysis: Reserved for Ca 18–20 mg/dL or patients with renal/heart failure where hydration is unsafe.

1. Bisphosphonates.
2. Denosumab: For bisphosphonate-refractory malignancy, the protocol is 120 mg subcutaneously weekly for four weeks, then monthly thereafter. Use with caution in renal failure (starting dose 0.3 mg/kg) to avoid profound hypocalcemia.
3. Glucocorticoids: Prednisone (20–40 mg) for calcitriol-mediated causes (sarcoid/lymphoma).
4. Calcimimetic agents (cinacalcet) reduce the serum calcium concentration in patients with severe hypercalcemia due to parathyroid carcinoma and in hemodialysis patients with an elevated calcium-phosphorus product and secondary hyperparathyroidism. 

10. Hypercalcemia of Malignancy: Clinical Focus

Malignancy-associated hypercalcemia often signifies advanced disease. Humoral hypercalcemia (PTHrP-mediated) occurs frequently in squamous cell and renal carcinomas. Serum PTHrP levels >12 pmol/L correlate with poorer prognosis and reduced response to bisphosphonates. In contrast, local osteolytic metastases are the hallmark of breast cancer and multiple myeloma.

11. Special Situations and Complications

• Milk-Alkali Syndrome: Triad of hypercalcemia, alkalosis, and renal insufficiency from excess calcium carbonate.
• CKD-MBD: Tertiary HPT reflects autonomous PTH production that may require surgical intervention even post-transplant.
• Long-term Complications: Chronic hypercalcemia causes nephrocalcinosis, chronic kidney disease, and cardiac valvular deposition.

12. Key Clinical Pearls

• Psychiatric Rule: In any patient with new-onset depression or psychosis, always check the serum calcium to exclude hyperparathyroidism.
• Renal Rule: If diabetes has been excluded in a patient presenting with polyuria, hypercalcemia must be investigated immediately.
• Sarcoidosis Warning: Never prescribe thiazides to patients with sarcoidosis; they risk precipitating a hypercalcemic crisis.
• Bridge Therapy: Always remember that calcitonin is a temporary bridge; its efficacy vanishes within 48 hours due to receptor downregulation.

13. FAQs 

1. What is the first test in hypercalcemia? After confirming the elevation with albumin-corrected calcium, measure intact PTH.
2. What level of calcium is a medical emergency? Levels >14 mg/dL (3.5 mmol/L) require immediate, aggressive intervention.
3. What is the most common cause in outpatients vs. inpatients? Primary HPT in outpatients; malignancy in hospitalized patients.
4. How do you distinguish FHH from primary HPT? 24-hour urinary calcium excretion is low in FHH (ratio < 0.01) and high or normal in primary HPT.
5. Why is calcitonin only for short-term use? Tachyphylaxis (rapid resistance) occurs within 48 hours as receptors downregulate.

14. References 

• Churchill's Pocketbook of Differential Diagnosis
• Clinical manifestations of hypercalcemia
• Diagnostic approach to hypercalcemia
• Etiology of hypercalcemia
• Hypercalcemia in granulomatous diseases
• Hypercalcemia of Malignancy: Mechanisms
• Treatment of hypercalcemia
• Algorithmic Diagnosis of Hypercalcemia